OPUS GENETICS INC(IRD)

POST4.740.07+1.57%19:33 EDT

4.67+0.07+1.52%

CommunityCommunity
NewsNews
ProfileProfile
AnnouncementsAnnouncements

- Opus Genetics to Report Phase 1/2 Cohort 1 Topline Data for OPGx-BEST1 Gene Therapy Sept. 9 Webcast
  Reuters · 09-02
  Opus Genetics to Report Phase 1/2 Cohort 1 Topline Data for OPGx-BEST1 Gene Therapy Sept. 9 Webcast
- Longeveron Appoints Nirav Jhaveri as Chief Financial Officer
  THOMSON REUTERS · 08-20
  Longeveron Appoints Nirav Jhaveri as Chief Financial Officer
- Longeveron - Marie Washburn Steps Down as CFO, Returns to Corporate Controller Role
  THOMSON REUTERS · 08-20
  Longeveron - Marie Washburn Steps Down as CFO, Returns to Corporate Controller Role
- Opus Genetics Grants Options for 310,000 Shares Under Inducement Plan
  Reuters · 08-20
  Opus Genetics Grants Options for 310,000 Shares Under Inducement Plan
- Opus Genetics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  THOMSON REUTERS · 08-20
  Opus Genetics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- Opus Genetics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary
  Reuters · 08-11
  Opus Genetics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary
- Opus Genetics (IRD) Receives a Buy from Piper Sandler
  TIPRANKS · 08-07
  Opus Genetics (IRD) Receives a Buy from Piper Sandler
- Cantor Fitzgerald Sticks to Their Buy Rating for Opus Genetics (IRD)
  TIPRANKS · 08-07
  Cantor Fitzgerald Sticks to Their Buy Rating for Opus Genetics (IRD)
- RBC Adjusts PT on Opus Genetics to $9 From $10, Maintains Outperform Speculative Risk Rating
  MT Newswires Live · 08-07
  RBC Adjusts PT on Opus Genetics to $9 From $10, Maintains Outperform Speculative Risk Rating
- Opus Genetics Inc Expected to Post a Loss of 16 Cents a Share - Earnings Preview
  Reuters · 08-07
  Opus Genetics Inc Expected to Post a Loss of 16 Cents a Share - Earnings Preview
- Opus Genetics - May Offer and Sell up to $300 Mln of Securities - SEC Filing
  THOMSON REUTERS · 08-07
  Opus Genetics - May Offer and Sell up to $300 Mln of Securities - SEC Filing
- Wall Street Analysts Are Bullish on Top Healthcare Picks
  TIPRANKS · 08-07
  Wall Street Analysts Are Bullish on Top Healthcare Picks
- Opus Genetics Q2 EPS $(0.14) Beats $(0.16) Estimate, Sales $755.000K Miss $2.470M Estimate
  Benzinga Earnings · 08-06
  Opus Genetics Q2 EPS $(0.14) Beats $(0.16) Estimate, Sales $755.000K Miss $2.470M Estimate
- Opus Genetics Q2 FY26 Net Loss Widens to $8.1 Million; Revenue Drops to $755,000
  Reuters · 08-06
  Opus Genetics Q2 FY26 Net Loss Widens to $8.1 Million; Revenue Drops to $755,000
- Opus Genetics Inc Q2 Pretax Profit USD -8.098 Million
  THOMSON REUTERS · 08-06
  Opus Genetics Inc Q2 Pretax Profit USD -8.098 Million
- Press Release: Opus Genetics Announces Financial Results for Second Quarter 2026 and Provides Corporate Update
  Dow Jones · 08-06
  Press Release: Opus Genetics Announces Financial Results for Second Quarter 2026 and Provides Corporate Update
- Wall Street Analysts Are Bullish on Top Healthcare Picks
  TIPRANKS · 08-04
  Wall Street Analysts Are Bullish on Top Healthcare Picks
- Opus Genetics Completes Enrollment in Phase 3 Gene Therapy Trial for Rare Blindness Disorder
  MT Newswires Live · 08-03
  Opus Genetics Completes Enrollment in Phase 3 Gene Therapy Trial for Rare Blindness Disorder
- Opus Genetics Completes Patient Enrollment in Registrational Phase 3 Trial of Opgx-Lca5 for Lca5-Associated Inherited Retinal Disease
  THOMSON REUTERS · 08-03
  Opus Genetics Completes Patient Enrollment in Registrational Phase 3 Trial of Opgx-Lca5 for Lca5-Associated Inherited Retinal Disease
- Opus Genetics - May Submit Bla Based on Six-Month Efficacy Data
  THOMSON REUTERS · 08-03
  Opus Genetics - May Submit Bla Based on Six-Month Efficacy Data
Company Profile
Company Name
OPUS GENETICS INC
Market
NASDAQ
Establishment Date
- -
Employees
- -
Office Location
- -
Website
http://www.ocuphire.com;ir.opusgtx.com;www.opusgtx.com
Zip Code
- -
Phone
- -
Fax
- -
Introduction
Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy. The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications. The company was formerly known as Ocuphire Pharma, Inc. Opus Genetics, Inc. was founded in 2018 and is headquartered in Farmington Hills, Michigan.
- 09-04 04:11
  Proposed Sale Of Securities
  Form 144 - Report of proposed sale of securities
  Form 144 - Report of proposed sale of securities
- 08-14
  Beneficial Ownership Change
  Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
  Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
- 08-14
  Beneficial Ownership Change
  Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
  Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
- 08-14
  Beneficial Ownership Change
  Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
  Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
- 08-06
  Quarterly Report
  Form 10-Q - Quarterly report [Sections 13 or 15(d)]
  Form 10-Q - Quarterly report [Sections 13 or 15(d)]
- 08-06
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 07-24
  Proposed Sale Of Securities
  Form 144 - Report of proposed sale of securities
  Form 144 - Report of proposed sale of securities
- 07-24
  Proposed Sale Of Securities
  Form 144 - Report of proposed sale of securities
  Form 144 - Report of proposed sale of securities
- 07-24
  Proposed Sale Of Securities
  Form 144 - Report of proposed sale of securities
  Form 144 - Report of proposed sale of securities
- 07-24
  Proposed Sale Of Securities
  Form 144 - Report of proposed sale of securities
  Form 144 - Report of proposed sale of securities
- 06-16
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 06-16
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 05-15
  Beneficial Ownership Change
  Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
  Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
- 05-15
  Beneficial Ownership Change
  Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
  Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
- 05-15
  Beneficial Ownership Change
  Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
  Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

1D
5D
Day
Week
Month

Loading ...

High

4.80

Open

4.53

Volume%

0.96

Low

4.40

4.60

T/O Rate

3.43%

To The Moon

OPUS GENETICS INC(IRD)

Company Profile

Most Discussed